WOLFSPEED, INC. quarterly report, Q4 FY1997

Business Context and Reporting Period

Company: Cree Research, Inc. (Note: The filing metadata lists "WOLFSPEED, INC.", but the document text identifies the registrant as Cree Research, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 28, 1997.
Business Overview: The company manufactures light-emitting diodes (LEDs), wafer materials, and display products. It also engages in research and development, often funded by U.S. government contracts. The company recently changed its fiscal year to a 52/53-week year ending on the last Sunday in June.

Key Financial Metrics

MetricThree Months Ended Dec 28, 1997Six Months Ended Dec 28, 1997Six Months Ended Dec 31, 1996
Total Revenue$10,106,000$20,313,000$13,528,000
Net Income$1,472,000$2,640,000$2,264,000
Diluted EPS$0.11$0.20$0.17
Gross Margin (Product)39%37%29% (Prior Year)
Operating Cash Flow (6mo)$2,820,000
Cash and Equivalents (End of Period)$13,102,000
Long-Term Debt$3,259,000

Material Changes vs. Prior Period

  • Revenue Growth: Total revenue increased 55% for the quarter and 50% for the six-month period compared to the prior year. Excluding a one-time $2.6 million license fee in the prior year, revenue growth for the six-month period was 86%.
  • Product Revenue: Product revenue surged 79% (quarter) and 124% (six months), driven primarily by a 116% increase in LED sales due to volume shipments under a contract with Siemens AG.
  • Profitability: Net income rose significantly, aided by improved gross margins (39% vs. 29% prior year quarter) resulting from higher throughput and manufacturing yields.
  • Debt and Liquidity: The company incurred $3.26 million in long-term debt to finance the purchase of a new production facility. Cash and cash equivalents increased from $10.4 million to $13.1 million.
  • One-Time Items: The company recorded a $66,000 write-off of goodwill related to the Real Color Displays subsidiary. It also received $436,000 in insurance reimbursements related to legal defense and medical expenses.

Guidance, Outlook, and Risks

  • Siemens Contract: A second amendment to the Siemens agreement obligates the company to ship LED chips with a fixed contract price exceeding $6 million for the remainder of fiscal 1998. However, the contract stipulates declining average sales prices as volume increases.
  • Cost Reduction Strategy: Management emphasizes the critical need to lower unit costs to maintain margins amidst declining sales prices. Strategies include transitioning to two-inch wafers and a new "conductive buffer" LED technology expected to be 50% brighter and cheaper to produce.
  • Capital Expenditures: The company is investing approximately $9–10 million in a new facility in Durham, NC. Financing is secured via a $10 million term loan (8% interest), with $6.7 million remaining available.
  • Risks: Key risks include the inability to achieve projected cost reductions, delays in new product introductions, customer acceptance of new technologies, and reliance on a limited customer base for LED sales.
  • Legal: Consolidated securities class action lawsuits were dismissed with prejudice in November 1997 with no payment to plaintiffs.

Investor Verification Checklist

  • Siemens Volume vs. Price: Verify if the volume increases under the Siemens contract are sufficient to offset the mandated price reductions to sustain the 37-39% gross margin.
  • Cost Reduction Execution: Confirm the timeline and success of the transition to two-inch wafers and the conductive buffer technology, as these are critical to future profitability.
  • Debt Covenants: Review the specific covenants of the $10 million term loan, particularly the minimum tangible net worth requirement, to ensure compliance.
  • Customer Concentration: Assess the risk associated with reliance on Siemens for a significant portion of LED revenue and the progress in diversifying the customer base.
  • Government Funding: Monitor the status of U.S. government research contracts, as the mix of cost-share vs. cost-plus arrangements impacts revenue recognition and R&D expense classification.